Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge
Massachusetts
02139
United States
Tel: 617-679-5500
Fax: 617-679-5592
Website: http://www.iderapharma.com/
Email: info@iderapharma.com
About Idera Pharmaceuticals, Inc.
Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.For more information, visit www.iderapharma.com.
368 articles about Idera Pharmaceuticals, Inc.
-
Idera Pharmaceuticals, Inc. Broadens Toll-Like Receptor Programs
5/15/2006
-
Idera Pharmaceuticals, Inc. Management to Make Presentations At Biotechnology Industry Organization (BIO) 2006
4/6/2006
-
Idera Pharmaceuticals, Inc. Secures $19.5 Million In Funding; Proceeds To Fund Clinical Programs Targeting Toll-Like Receptors
3/26/2006
-
BioSpace, Inc. And Massachusetts Biotechnology Council, Inc. Unveil 2006 Genetown™ Campaign
12/15/2005
-
Idera Pharmaceuticals, Inc. Appoints Robert W. Karr, M.D. President Of The Company
12/6/2005
-
Idera Pharmaceuticals, Inc. to Present At Rodman And Renshaw Techvest 7th Annual Healthcare Conference
11/3/2005
-
Idera Pharmaceuticals, Inc. Initiates Phase 1/2 Oncology Trial Of HYB2055 In Combination With Chemotherapy Agents Gemcitabine And Carboplatin
10/26/2005
-
Idera Pharmaceuticals, Inc. Amends HYB2055 Phase 2 Renal Cell Carcinoma Protocol
10/20/2005